Disease Studies

COVID-19

At the beginning of the current pandemic, we offered the use of our PrecisionLife® platform to the global research community to analyze large scale, multi-omic, clinical and epidemiological data for COVID-19 datasets.

Since then we have worked with several international groups around our analysis results. We have generated multiple insights into the genetics, clinical presentation, pathology and treatment of COVID-19 patients that would not have been possible with existing analysis tools.

We continue to run new studies and to post new pre-prints and manuscripts. We have placed all of our COVID-19 results into the public domain. This has led us to working closely with scientists and clinicians battling the COVID-19 pandemic across the US, Denmark, Germany, Taiwan, and the UK.

If you’re interested in collaborating with us, have a COVID-19 dataset or would like more information on previous studies, please contact us at covid-19@precisionlife.com.


Previous papers / study results

Combinatorial analysis of phenotypic and clinical risk factors associated with hospitalized COVID-19 patients

February 11, 2021.

A study using de-identified clinical claims and labs data for US COVID-19 patients. We replicated previous findings around the potential role of calcium and lipid homeostasis in severe COVID-19.

We would like to acknowledge the UnitedHealth Group for providing us access to the COVID-19 Data Suite
through the UHG Clinical Discovery Portal and the patients who provided their data.

View the study

Analysis of Genetic Host Response Risk Factors in Severe COVID-19 Patients

June 25, 2020

We used a UK Biobank population designated with mild or severe COVID-19 to identify 68 genes associated with risk of developing a severe clinical response to SARS-CoV-2.

View the study

Shared genetic risk factors between sepsis and COVID-19

May 5, 2020

Our first COVID-19 study identified shared genetic risk factors for sepsis (a common clinical co-morbidity with severe COVID-19) and 59 drug repurposing candidates.

View the study

Current studies

The COVID-19 PHARMACOME: Rational Selection of Drug Repurposing Candidates from Multimodal Knowledge Harmonization

Manuscript submitted

Systematic analysis and mapping of drug repurposing experiments to integrated disease maps for SARS-CoV-2 / COVID-19.


Long COVID

PrecisionLife is working with Sano Genetics to identify genetic, clinical and epidemiological factors associated with long COVID in a 3,000 patient COVID-19 population.

Long COVID study

Genomics England

PrecisionLife is using the Genomics England Research Environment to evaluate the factors driving differential clinical outcomes (severity and longevity of disease) in a COVID-19 population.


Contact us

If you have any questions or would like to speak to us in terms of potential collaborations or partnership opportunities, please get in touch using the form below or email info@precisionlife.com and we will get back to you as soon as we can. Note that our Privacy Policy and Terms & Conditions apply.


UK

Unit 8b Bankside
Hanborough Business Park
Long Hanborough, OX29 8LJ

USA

1 Broadway Fl 14
Cambridge
MA 02142-1187

Denmark

Agern Allé 3
DK-2970
Hørsholm

Poland

CIC Ul
Chmielna 73m
00-801 Warszawa

  • This field is for validation purposes and should be left unchanged.